AstraZeneca plc 22.9% Potential Decrease Indicated by UBS

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Unchanged’ with the recommendation being set at ‘SELL’ today by analysts at UBS. AstraZeneca plc are listed in the Health Care sector within UK Main Market. UBS have set a target price of 5700 GBX on its stock. This would indicate that the analyst believes there is a downside of -22.9% from the opening price of 7392 GBX. Over the last 30 and 90 trading days the company share price has increased 1061 points and increased 1576 points respectively. The 1 year high for the stock price is 7475.15 GBX while the 52 week low for the share price is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 6,632.04 GBX and a 200 Day Moving Average share price is recorded at 6,195.61. There are currently 1,311,876,336 shares in issue with the average daily volume traded being 2,198,374. Market capitalisation for LON:AZN is £96,009,278,905 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search